Can a PET scan predict breast cancer drug success?

NCT ID NCT06179303

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times

Summary

This study tests whether a special PET scan can predict if a drug combination (abemaciclib plus hormone therapy) will work for people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants will get the treatment and have scans to see if the imaging can tell who will respond. The goal is to improve treatment decisions, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Siteman Cancer Center at Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.